Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Description

List of Tables

What is Cardiomyopathy?

Heterogenous collection of pathologies; normal heart muscle, stiff, thin, or fills with substances that do not belong
Dilated CM, Hypertrophic CM (Obstructive/Non-Obstructive), RCM, ACM
Symptoms: Shortness of breath/trouble breathing, fatigue, swelling in the ankles, feet, legs, abdomen and veins, dizziness, light-headedness, fainting during physical activity, etc.

How is Cardiomyopathy managed?

No treatment
Generics: Beta blockers, ACE inhibitors, ARBs, antiarrhythmics, calcium channel blockers
Branded: SGLT2 inhibitors
Surgically implanted devices, alcohol ablation, etc.

Why Cardiomyopathy?

First report covering CM
New pipeline products that are expected to be blockbusters:

Camzyos (mavacamten) & aficamten

First drugs to be indicated for obstructive HCM
First myosin inhibitors
More closely address underlying pathophysiology of the disease

GlobalData projects the therapeutic market for cardiomyopathies within the 7MM will grow from $1.6B in 2021 at a compound annual growth rate (CAGR) of 12.4% to $5.2B by 2031.

Main drivers of growth:

Camzyos (Bristol Myers Squibb) and aficamten (Cytokinetics) launch across the 7MM
Entresto (sacubitril + valsartan) label expansion to include CM

KEY QUESTIONS ANSWERED

Treatment for cardiomyopathies should improve over the forecast period, but unmet needs remain.

Which unmet needs are the most pressing in the 7MM?
Where should pharmaceutical companies focus drug development efforts in order to become a significant player in the space?

Novel drugs are being developed, with 65 pipeline candidates from pre-registration to Phase III.

What are the most promising late-stage candidates and how much they expected to generate over the forecast period?
What do KOLs say about their clinical and commercial positioning?

An increasing number of companies are investing in cardiomyopathies drug development.

Which have been historically the companies leading the way?
What new companies are emerging in the space?

Key Highlights

The cardiomyopathies market is currently highly genericized and contains many off-label medications, which provide affordable options with limited side effects. These factors create a stiff barrier for entry of novel therapeutics, but pipeline therapeutics will find success due to strong efficacy and safety profiles and that they are cardiomyopathy-specific therapeutics, rather than general cardiovascular drugs.
There is an increased focus on genetic screening and developing genetic therapeutics because cardiomyopathies are often inherited rather than acquired. Emprumapimod will be the first marketed genetic therapy, as it targets patients with DCM due to a lamin gene mutation. However, this drug will not generate significant revenue given the small size of the target patient population.
There is not a cure for cardiomyopathies, instead the disease symptoms are managed with generic cardiovascular drugs. This remains an area of unmet need in the cardiomyopathies space.
Camzyos was the first novel therapy launched in the cardiomyopathies market in several decades when it was marketed in 2022. Thus, there is a need for novel therapies in this space, which should be met by the extensive pipeline.

Scope

Overview of cardiomyopathies including epidemiology, disease etiology and management.
Topline cardiomyopathy drugs market revenue (including off-label adjunct therapeutics used for metabolic benefits), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global cardiomyopathy therapeutics market. Insightful review of the key industry drivers, restraints and challenges.

Reasons to Buy

The report will enable you to -

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global cardiomyopathy therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global cardiomyopathies market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global cardiomyopathy therapeutics market from 2021-2031.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC247PIDR

1 Cardiomyopathies: Executive Summary

1.1 The cardiomyopathies market will experience significant growth between 2021 and 2021
1.2 Label expansion is a current and future growth strategy for companies in the cardiomyopathies space
1.3 Curative therapy options and improvements in genetic screening remain areas of need
1.4 Camzyos to drive cardiomyopathy sales during the forecast period
1.5 What do physicians think?

2 Introduction

2.1 Catalyst
2.2 Related reports

3 Disease Overview

3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease Background
- 4.1.1 Risk Factors and Comorbidities
4.2 Global and Historical Trends
4.3 Forecast Methodology
4.4 Epidemiological Forecast for Cardiomyopathies (2021-2031)
4.5 Discussion

5 Disease Management

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Improvements in genetic screening and gene therapies
7.3 Curative rather than preventative therapy options
7.4 Newer drugs with specific targets
7.5 Adequate diagnosis and treatment of amyloid cardiomyopathy patients

8 R&D Strategies

8.1 Overview
- 8.1.1 Label expansion
- 8.1.2 Development of drugs with novel targets
8.2 Clinical trial design
- 8.2.1 Quality of life endpoints

9 Pipeline Assessment

9.1 Overview
9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive assessment

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends

12 Market Outlook

13 Appendix

Product Code: GDHC247PIDR

List of Tables

Table 1: Cardiomyopathies: Key Metrics in the 7MM
Table 2: Cardiomyopathies: Features and factors
Table 3: Risk factors and comorbidities for cardiomyopathies
Table 4: Most commonly used guidelines for cardiomyopathies by country
Table 5: Pfizer Portfolio Assessment, 2022
Table 6: Bristol Myers Squibb Portfolio Assessment, 2022
Table 7: Cytokinetics Portfolio Assessment, 2022
Table 8: Cardiomyopathies market - global drivers and barriers, 2021-2031
Table 9: Key events impacting sales for cardiomyopathies in the US, 2021-2031
Table 10: Cardiomyopathies Market - Drivers and Barriers in the US, 2021-2031
Table 11: Key events impacting sales for cardiomyopathies in the 5EU, 2021-2031
Table 12: Cardiomyopathies market - drivers and barriers in the 5EU, 2021-2031
Table 13: Key events impacting sales for cardiomyopathies in Japan, 2021-2031
Table 14: Cardiomyopathies market - drivers and barriers in Japan, 2021-2031
Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

Figure 1: Global sales forecast by country for cardiomyopathies in 2021 and 2031
Figure 2: Analysis of the company portfolio gap in cardiomyopathies during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of cardiomyopathies during the forecast period
Figure 4: Physical differences between a normal heart and hearts afflicted with dilated, hypertrophic, and restrictive cardiomyopathies
Figure 5: 7MM, diagnosed prevalence of cardiomyopathies (%), men and women, all ages, 2021
Figure 6: Sources used and not used for diagnosed prevalent cases of dilated cardiomyopathy
Figure 7: Sources used and not used for diagnosed prevalent cases of hypertrophic cardiomyopathy
Figure 8: Sources used for diagnosed prevalent cases of restrictive cardiomyopathy
Figure 9: Sources used for diagnosed prevalent cases of arrhythmogenic cardiomyopathy
Figure 10: Sources used for diagnosed prevalent cases of dilated cardiomyopathy by etiology
Figure 11: Sources used for diagnosed prevalent cases of hypertrophic cardiomyopathy by etiology
Figure 12: Sources used for diagnosed prevalent cases of restrictive cardiomyopathy by etiology
Figure 13: Sources used for diagnosed prevalent cases of arrhythmogenic cardiomyopathy by etiology
Figure 14: 7MM, diagnosed prevalent cases of cardiomyopathies in 2021, men and women, N, all ages
Figure 15: 7MM, diagnosed prevalent cases of cardiomyopathies by subtype, men and women, all ages, N, 2021
Figure 16: 7MM, age-specific diagnosed prevalent cases of cardiomyopathies, men and women, all ages, N, 2021
Figure 17: 7MM, diagnosed prevalent cases of cardiomyopathies by sex, all ages, N, 2021
Figure 18: 7MM, Diagnosed Prevalent Cases of Cardiomyopathies by Etiology, Men and Women, All Ages, N, 2021
Figure 19: 7MM, diagnosed prevalent cases of ischemic dilated cardiomyopathy, men and women, all ages, N, 2021
Figure 20: Sample cardiomyopathy treatment paradigm
Figure 21: Unmet needs and opportunities in cardiomyopathy
Figure 22: Overview of the development pipeline in cardiomyopathies
Figure 23: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for cardiomyopathy in the 7MM during the forecast period
Figure 24: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of cardiomyopathies during the forecast period
Figure 25: Competitive assessment of the marketed and pipeline drugs benchmarked against the standard of care: ACE inhibitors, ARBs, ARNi (Entresto), beta blockers, MRAs, SGLT2 inhibitors, antiarrhythmics, and calcium channel blockers
Figure 26: Analysis of the company portfolio gap in cardiomyopathies during the forecast period
Figure 27: Deal-Making Trends, 2017-2021
Figure 28: Global (7MM) sales forecast by country for cardiomyopathies in 2021 and 2031
Figure 29: Sales forecast by class for cardiomyopathies in the US in 2021 and 2031
Figure 30: Sales forecast by class for cardiomyopathies in the 5EU in 2021 and 2031
Figure 31: Sales forecast by class for cardiomyopathies in Japan in 2021 and 2031

Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Description

Table of Contents

List of Tables

KEY QUESTIONS ANSWERED

Key Highlights

Scope

Reasons to Buy

Table of Contents

Table of Contents

1 Cardiomyopathies: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

12 Market Outlook

13 Appendix

List of Tables

List of Tables

List of Figures

List of Figures